WilmerHale represented the underwriters in the initial public offering of 12,100,000 shares of common stock of CinCor Pharma, a clinical-stage biopharmaceutical company, at an initial public offering price of $16.00 per share. The underwriters have a 30-day option to purchase up to an additional 1,815,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions. The offering priced on January 6, 2022, and closed on January 11, 2022. The gross proceeds to the company were $193.6 million.

The WilmerHale team advising the underwriters consisted of Lisa Firenze, Ryan Brewer, Frank Wang, Bruce Manheim, Colleen Superko and Heidi Treiber.

For more information, read CinCor Pharma’s press release.